<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02198300</url>
  </required_header>
  <id_info>
    <org_study_id>2.1</org_study_id>
    <nct_id>NCT02198300</nct_id>
  </id_info>
  <brief_title>DES Versus BiOSS LIM - POLBOS II Study</brief_title>
  <acronym>POLBOS II</acronym>
  <official_title>Regular Drug Eluting Stent Versus Dedicated Bifurcation Sirolimus-eluting Stent BiOSS LIM in Coronary Bifurcation Treatment - Randomized POLBOS II Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Clinical Hospital of the Ministry of Internal Affairs and Administration, Warsaw, Poland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central Clinical Hospital of the Ministry of Internal Affairs and Administration, Warsaw, Poland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Coronary bifurcation lesions pose therapeutic problems during percutaneous coronary
      interventions (PCI) and are associated with higher rates of periprocedural complications as
      well as higher rates of in-stent restenosis and stent thrombosis. Provisional T-stenting
      (PTS) is the best treatment strategy at the moment. However, the optimal approach to coronary
      bifurcations treatment is still a subject of debate, especially when the side branch is
      large, not easily accessible and narrowed by a long lesion. One of the proposed alternatives
      are dedicated bifurcation stents (DBS). However, there is large scarcity of randomized trials
      with DBS. POLBOS II study is continuation of POLBOS I (POLish Bifurcation Optimal Stenting)
      study, in which paclitaxel-eluting stent BiOSS Expert® (Balton, Poland) was assessed. Now
      performance of sirolimus-eluting stent BiOSS LIM® (Balton, Poland) is verified.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After signing the informed consent patients were randomly assigned to one of two treatment
      strategies: BiOSS LIM® stent implantation or rDES implantation (envelope randomization, 1:1).
      If the patient was enrolled to rDES Group there was a second randomization: with or without
      final kissing ballooning (FKB). Clinical follow-up was performed with office visits or
      telephone contacts at 1 and 12 months after intervention. Adverse events were monitored
      throughout the study period. Follow-up coronary angiography was performed at 12 months unless
      clinically indicated earlier.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MACE</measure>
    <time_frame>12 months</time_frame>
    <description>Cumulative rate of major adverse cardiovascular events (MACE) including cardiac death, myocardial infarction (MI) and repeated revascularization of the target lesion (TLR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>cardiac death</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>all-cause death</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MI</measure>
    <time_frame>12 months</time_frame>
    <description>myocardial infarction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TLR</measure>
    <time_frame>12 months</time_frame>
    <description>target lesion revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TVR</measure>
    <time_frame>12 months</time_frame>
    <description>target vessel revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LLL</measure>
    <time_frame>12 months</time_frame>
    <description>late lumen loss</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">202</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>rDES Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>regular drug-eluting stent implantation in coronary lesion within bifurcation LucChopin Xience Promus Resolute Integrity Biomatrix Prolim</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BiOSS LIM Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BiOSS LIM® stent implantation into coronary lesion within bifurcation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Coronary angioplasty with stent implantation</intervention_name>
    <arm_group_label>rDES Group</arm_group_label>
    <arm_group_label>BiOSS LIM Group</arm_group_label>
    <other_name>device: LucChopin (Balton, Poland)</other_name>
    <other_name>device: Xience (Abbot Vascular)</other_name>
    <other_name>device: Promus (Boston Scientific)</other_name>
    <other_name>device: Resolute Integrity (Medtronic)</other_name>
    <other_name>device: Biomatrix (Biosensors)</other_name>
    <other_name>device: Prolim (Balton, Poland)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dual antipletlet therapy (DAPT)</intervention_name>
    <description>DAPT given to each patient before stent implantation</description>
    <arm_group_label>rDES Group</arm_group_label>
    <arm_group_label>BiOSS LIM Group</arm_group_label>
    <other_name>acetysalicylic acid</other_name>
    <other_name>clopidogrel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  stable coronary artery disease (CAD) or non-ST-segment elevation acute coronary
             syndrome (NSTE-ACS)

          -  age ≥ 18 years old,

          -  de novo coronary bifurcation lesion (including unprotected LMS),

          -  MV diameter ≥ 2.5 mm and SB diameter ≥ 2.0 mm assessed by visual estimation.

        Exclusion Criteria:

          -  ST-elevation myocardial infarction (STEMI),

          -  bifurcations with Medina type 0,0,1,

          -  serum creatinine level ≥ 2.0 mg/dl,

          -  inability to take dual antiplatelet therapy for 12 months,

          -  left ejection fraction ≤ 30%

          -  lack of an informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert J Gil, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Central Clinical Hospital of the Ministry of Internal Affairs and Administration, Warsaw, Poland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Central Clinical Hospital of the Ministry of Interior</name>
      <address>
        <city>Warsaw</city>
        <state>Mazowieckie</state>
        <zip>02-507</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <reference>
    <citation>Bil J, Gil RJ, Vassilev D, Rzezak J, Kulawik T, Pawlowski T. Dedicated bifurcation paclitaxel-eluting stent BiOSS Expert® in the treatment of distal left main stem stenosis. J Interv Cardiol. 2014 Jun;27(3):242-51. doi: 10.1111/joic.12119. Epub 2014 Apr 7.</citation>
    <PMID>24708143</PMID>
  </reference>
  <reference>
    <citation>Vassilev D, Mateev H, Alexandrov A, Stankev M, Rigatelli G, Gil RJ. Stenting below-the-knee bifurcations with dedicated bifurcation stent BiOSS Lim - first in man case report. Cardiovasc Revasc Med. 2014 Apr;15(3):171-7. doi: 10.1016/j.carrev.2013.09.005. Epub 2013 Oct 22.</citation>
    <PMID>24157310</PMID>
  </reference>
  <reference>
    <citation>Gil RJ, Bil J, Michałek A, Vassiliev D, Costa RA. Comparative analysis of lumen enlargement mechanisms achieved with the bifurcation dedicated BiOSS) stent versus classical coronary stent implantations by means of provisional side branch stenting strategy: an intravascular ultrasound study. Int J Cardiovasc Imaging. 2013 Dec;29(8):1667-76. doi: 10.1007/s10554-013-0264-0. Epub 2013 Jul 19.</citation>
    <PMID>23868287</PMID>
  </reference>
  <reference>
    <citation>Gil RJ, Vassilev D, Michalek A, Kern A, Formuszewicz R, Dobrzycki S, Wójcik J, Lesiak M, Kardaszewicz P, Lekston A. Dedicated paclitaxel-eluting bifurcation stent BiOSS® (bifurcation optimisation stent system): 12-month results from a prospective registry of consecutive all-comers population. EuroIntervention. 2012 Jul 20;8(3):316-24. doi: 10.4244/EIJV8I3A50.</citation>
    <PMID>22829507</PMID>
  </reference>
  <reference>
    <citation>Vassilev D, Gil R, Milewski K. Bifurcation Optimisation Stent System (BiOSS Lim) with sirolimus elution: results from porcine coronary artery model. EuroIntervention. 2011 Sep;7(5):614-20. doi: 10.4244/EIJV7I5A98.</citation>
    <PMID>21930466</PMID>
  </reference>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 20, 2014</study_first_submitted>
  <study_first_submitted_qc>July 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 23, 2014</study_first_posted>
  <last_update_submitted>July 28, 2015</last_update_submitted>
  <last_update_submitted_qc>July 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Central Clinical Hospital of the Ministry of Internal Affairs and Administration, Warsaw, Poland</investigator_affiliation>
    <investigator_full_name>Jacek Bil</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>dedicated bifurcation stent</keyword>
  <keyword>sirolimus eluting stent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

